This website uses cookies

We use cookies to personalize content and ads, to provide social media features and to analyze our traffic. We also share information about your use of our site with our social media, advertising and analytics partners who may combine it with other information that you’ve provided to them or that they’ve collected from your use of their services. We will only use cookies based on your decision.

DCA Vantage Analyzer Meets Performance Criteria for Hemoglobin A1c TestingHealthcare News | March 25, 2010

DCA Vantage Analyzer Meets Performance Criteria for Hemoglobin A1c Testing

Siemens is proud to announce that – according to an independent study – our DCA Vantage® Analyzer is one of just two HbA1c analyzers that meets tightened performance criteria set by the NGSP*.

The European Reference Laboratory for Glycohemoglobin study’s results were published in Clinical Chemistry as "Six of Eight Hemoglobin A1c Point-of-Care Instruments Do Not Meet the General Accepted Analytical Performance Criteria" (January 2010, 56:1).

The study objective was to "evaluate all available HbA1c POC instruments according to CLSI protocols and to check whether the instruments would pass the NGSP criteria with 2 different reagent lot numbers."1

HbA1c analyzers evaluated were:

  • A1c Now (Bayer)
  • Afinion and Nycocard (Axis-Shield)
  • Clover (Infopia)
  • DCA Vantage (Siemens)
  • In2it (BioRad)
  • InnovaStar (Diasys)
  • Quo-Test (Quotient Diagnostics) 

According to the results, only two POC instruments met the acceptance criteria and the DCA Vantage analyzer was one of them.

Read the full article, "Six of Eight Hemoglobin A1c Point-of-Care Instruments Do Not Meet the General Accepted Analytical Performance Criteria", on Clinical Chemistry

The DCA Vantage Analyzer now provides dual reporting, using the IFCC-NGSP master equation.

1
Subscription Button Icon
Be the first to know about our events, training, and news